Skip to main content
. Author manuscript; available in PMC: 2014 Apr 1.
Published in final edited form as: Hypertension. 2013 Feb 25;61(4):842–849. doi: 10.1161/HYPERTENSIONAHA.111.00080

Figure 8.

Figure 8

Schematic diagram showing possible mechanisms by which p44/42 MAPK activity in the PVN might contribute to ANG II-induced hypertension. Early PVN microinjections of p44/42 MAPK siRNA inhibit ANG II-induced p44/42 MAPK activity to reduce upregulation of AT1R in the PVN, resulting in decreased blood pressure mediated by sympathetic excitation during the development of hypertension. ANG II also induces upregulation of inflammatory mediators, independent of p44/42 MAPK, and these may contribute to the subsequent progression of hypertension.